Fundraising Fox
Aviceda Therapeutics
Cambridge, US · Founded 2019 · Delaware corporation · 18 employees on LinkedIn · 7 known investors
Find your way into Aviceda Therapeutics
590 people in our graph share verified history with the Aviceda Therapeutics team — schools, employers, funds. One of them is your warm intro.
Michael Fennunlockedknows Mohamed Genead · together at Arionix Therapeutics Inc. (overlapped)
knows the team · via Penn Medicine, University of Pennsylvania Health System
knows the team · via U.S. Department of Veterans Affairs
×6knows the team · via Allergan
×3knows the team · via Atlas Venture
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
Founders & leadership
Aviceda Therapeutics was founded in 2019 by Mohamed Genead, Michael Tolentino, and Mohamed A. Genead.
MG
Mohamed GeneadCo-Founder, CEO & President, Executive Board Director2017–2024Mohamed Genead is a co-founder of multiple biotechnology companies, including Aviceda Therapeutics, and holds an ophthalmology background with clinical expertise. He has served as CEO of Aviceda and co-invented several foundational biotech patents, with experience spanning immunology, cell and gene therapy, and clinical development across oncology and neurology indications.
MT
Michael TolentinoCo-Founder, Senior Scientific Advisor to the CEO2025–2025Michael Tolentino is a retinal surgeon and therapeutic researcher who studied VEGF signaling in macular degeneration and diabetic retinopathy at Harvard Medical School, developed anti-angiogenic and gene therapy approaches at the University of Pennsylvania, and founded or co-founded Aviceda Therapeutics, Aviceda Glycotech, and Avilect Biosciences, serving as chief technology officer and board member across these companies.
MA
Mohamed A. GeneadChairman & CEOMohamed A. Genead is an ophthalmologist and co-founder of multiple biotechnology companies including Aviceda Therapeutics, Aviceda Glytech Ltd, Arionix Therapeutics, and CarThena Therapeutics, with experience in clinical development and business operations across oncology, immunology, fibrosis, and neurology.
Board
DG
David GuyerBoard director
NT
Nancy ThomasonBoard director
CA
Christoph AdamsBoard director
EL
Erin LavelleBoard director
Investors · 7
Jeito Capital✓ confirmed by Aviceda TherapeuticsParis
How we know: Jeito Capital's portfolio page · the company's own site · funding news · Not right? Tell us
Longitude Capital✓ confirmed by Aviceda TherapeuticsMenlo Park · $10M – $30M
How we know: the company's own site · Longitude Capital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
Avoro Capital AdvisorsreportedNew York
How we know: a partner's Signal profile · Not right? Tell us
Digitalis VenturesreportedNew York · $100K – $10M
How we know: the VCSheet dataset · Not right? Tell us
Omega FundsreportedBoston
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$173.6M disclosed across 7 rounds · 2020–2024
▶$75MraisedJan 2025 · 17 investors · BiotechnologyRule 506(b)
▶$75MraisedJan 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David CallananExecutive Officer
- Nancy ThomasonDirector
- Mohamed GeneadExecutive Officer, Director
- Michael TolentinoExecutive Officer, Director
- Christoph AdamsDirector
- Tarek HassanExecutive Officer
- Erin LavelleDirector
- David GuyerDirector
- Derek KunimotoExecutive Officer
- Jay WoodsDirector
- Offering amount
- $207.5M
- Amount sold
- $75M
- Sales commissions
- $5M
- Placement agents
- Leerink Partners LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.9MraisedMay 2024 · 18 investors · BiotechnologyRule 506(b)
▶$18.9MraisedMay 2024 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nancy ThomasonDirector
- Michael TolentinoDirector
- Christoph AdamsDirector
- Patrick JohnsonDirector
- Jay WoodsDirector
- Mohamed GeneadExecutive Officer, Director
- Offering amount
- $27.7M
- Amount sold
- $18.9M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$15.6MraisedMay 2023 · 11 investors · BiotechnologyRule 506(b)
▶$15.6MraisedMay 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nancy ThomasonDirector
- Patrick JohnsonDirector
- Mohamed GeneadExecutive Officer, Director
- Michael TolentinoDirector
- Christoph AdamsDirector
- Paul VukelicDirector
- Offering amount
- $15.6M
- Amount sold
- $15.6M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$49.5MraisedMar 2022 · 11 investors · Other TechnologyRule 506(b)
▶$49.5MraisedMar 2022 · 11 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Dmytro VoloshynDirector
- Ross DarwinDirector
- Robert KniazDirector
- Mariusz GralewskiDirector
- Kyrylo BigayExecutive Officer, Director
- Offering amount
- $79.7M
- Amount sold
- $49.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MraisedMar 2022 · 16 investors · BiotechnologyRule 506(b)
▶$8.4MraisedMar 2022 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael TolentinoDirector
- Derek KunimotoDirector
- Mohamed GeneadExecutive Officer
- Offering amount
- $26.2M
- Amount sold
- $8.4M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.9MraisedAug 2021 · 7 investors · OtherRule 506(b)
▶$1.9MraisedAug 2021 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mohamed GeneadExecutive Officer, Director
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.3MraisedSep 2020 · 15 investors · OtherRule 506(b)
▶$4.3MraisedSep 2020 · 15 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Derek KunimotoExecutive Officer, Director
- Michael TolentinoDirector
- Mohamed A. GeneadExecutive Officer, Director
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Aviceda Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Aviceda Therapeutics do?
- Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
- Who founded Aviceda Therapeutics?
- Aviceda Therapeutics was founded by Mohamed Genead, Michael Tolentino, Mohamed A. Genead in 2019.
- Who are Aviceda Therapeutics's investors?
- Aviceda Therapeutics's investors include Jeito Capital, Longitude Capital, Catalio Capital Management, LP, OrbiMed, Avoro Capital Advisors, Digitalis Ventures, Omega Funds.
- How much funding has Aviceda Therapeutics raised?
- Aviceda Therapeutics has disclosed $173.6M raised across 7 rounds.
- Where is Aviceda Therapeutics headquartered?
- Aviceda Therapeutics is headquartered in Cambridge, US.